Other substances

Digoxin

Cardiotonic agent

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Marketed as

Lanoxin

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Preprint Screening	VERO cells			Mar/19/2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 Small molecule In vitro Screening	Vero cells	5.09		Nov/25/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells		higher IC50 value in Calu-3 cells than VERO E6 cells	May/12/2020

AI-suggested references

Link	Publication date
Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein.	May/13/2022
Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2	Dec/07/2020
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19	Oct/01/2020
Leveraging knowledge of Asian herbal medicine and its active compounds as COVID-19 treatment and prevention	Nov/14/2020
Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19	Nov/23/2020
Multi-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease	Jan/17/2022
Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells	Nov/12/2021